Lightjump Acquisition Corp

Lightjump Acquisition — SPAC Merger (June 2022)

42 slides from Lightjump Acquisition's SPAC merger presentation, Jun 15, 2022

  1. Slide 1: Science in Alternative Proteins – Investor Presentation June 2022

    ' Moolec J LightJump* SCIENCE IN ALTERNATIVE PROTEINS Investor Presentation June 2022

  2. Slide 2: Disclaimer and Forward-Looking Statements

    ‘This presentation was prepared for informational purposes only by Moolec Science Limited, ’Moole) and LightJump Acquisition Corporation C"LightJump") and is intended to be provided only to accredited institutional investors who are considering an investment in Molec. The information provided inthis

  3. Slide 3: Presenters

    LightJump Robert Bennett CChaieman & CEO 25+ years equity sponsor in technology, advanced manu facturing, and digital media, Co-Founder and CEO of View Market (sold to Gow Media). Co-Founder of multiple IT services companies Union Acquisition Group Kyle P. Bransfield CEO & Co-Founder ‘CEO & Director

  4. Slide 4: Overview of SPAC Business Combination, Capital Structure, and Use of Proceeds

    Overview, of SPAC Business Combination, Capital Structure, and Use of Proceeds Moolec & LJ Business Combination Lightjump Acquisition Corp. (NASDAQ: LJAQ) is a $138M listed SPAC with deep private equity experience in ‘emerging technologies. Moolec Science Limited (Moolec) is an early stage FoodTech

  5. Slide 5: Transaction Overview – Capitalization, Sources, and Uses

    Transaction Overview, - Capitalization, Sources, and Uses Transaction Sources and Uses Redemptions Scenarios LJAQ cash in trust? $138M $69M SOM Moolec Shares (rollover equity) $325M $325M $325M Backstop © SOM $OM $IOM Total Sources $463M $394M $335M Uses 0% 50% 1009 Cash to Surviving Company Balance

  6. Slide 6: Investment Highlights

    Investment Highlights. r of Ath technological d st impact chi le proposition pillar within the alternative protein segment (ingredients) of the with cost, scale, nutrition and industry as a category creator marketplace organoleptic advantages anding'Strategic id industry trends ry hip team with part

  7. Slide 7: Moolec is a company using Molecular Farming technology

    # Moolec is a Moolec ~, C company using Molecular Farming technology. Our purpose is to upgrade taste, nutrition, and affordability of alternative protein ~ products while building a more sustainable 2 and equitable food system. SCIENCE IN

  8. Slide 8: Moolec by the Numbers

    Moolec by the,Numbers, Moolec is pioneering the future of alternative protein ingredient production 1st To achieve a bovine protein with plants for food 60X Less GHG Emissions vs. Cattle Farming? 100% Animal-Free 4 Key Alliances with crop science and pharmaceutical players SCIENCE IN

  9. Slide 9: ~~ 2—

    ~~ 2—

  10. Slide 10: Present Context: Ring of Fire

    Present Context: Ring.of.Fire COVID-19 has amplified the weakness of the global food supply chain and the:dismal outlook on food security 090 Human Health® (fq? * War in Ukraine is * Long-term consumption of amplifying global meat highly correlated food crisis? with earlymorbidityand cardiovascular

  11. Slide 11: The world needs more and sustainable food

    The world needs more and sustainable food Population growth could reach 10 billion people by the year 2050 Crop production would need to double to support the demand Inefficient conversion! Unsustainable system? Consumer’s Shift? eee Sor. 40% 05406 + = e rm 25kg 15.400 Its Croplands GHG Vegetarian,

  12. Slide 12: Alternative proteins emerged to address the problems

    A! Seen insaciia emerged to address the problems Companies use different technologies and ingredients based on plants, cells, and microbes Plant-Based! Products made from plants that are alternatives to animal-based products. This includes plant-based meat, seafood, eggs, and dairy Fermentation? Use

  13. Slide 13: Total Addressable Market

    300 200 100 Total Addressable Market, Alternative protein consumption projections (retail prices)! 2030 2035 PROTEINS.

  14. Slide 14: The challenge: Reach parity with animal-based food

    he.challenge: Reach parity with animal-based food Nutritional values Taste and texture Scalability and low costs SCIENCE IN

  15. Slide 15: The solution: Moolec as Category Creator

    The solution: Moolec as Gategory.Greator et & © CD Plant-based Fermentation Cultured meat Molecular Farming Taste and texture (x) Cv) iv) @ Nutritional values (x) tv) iv) @ Scalability and low costs (v) (x) (x) (v) Plants Science Plants + Science

  16. Slide 16: ~~ 2—

    ~~ 2—

  17. Slide 17: Moolec's technology

    pio arcs ins We introduce the real DNA of proteins’ genes to the seeds of the main plants used in food to give back real taste and nutrition to products using Molecular Farming technologies Moolec’s Technology plant-based animal proteing . «erin Animal Proteins - Genetic enginee'

  18. Slide 18: Molecular Farming: A cost-effective way to produce Alternative Proteins

    Molecular Farming: A cost-effective way to produce Alternative Proteins’ Plants as Bioreactors No extra purification cost Economy of scale We use plants as small We mix animal and plant We use the hectares of farming factories, without extra energy proteins saving the extra to achieve volume, produc

  19. Slide 19: Molecular Farming vs. Animal-based production system

    Molecular Farming vs. Animal-based, production system 35X less’ 8X less? 60x less* Land Usage Water Footprint CO2Emissions

  20. Slide 20: Molecular Farming Landscape

    Molecular Farming Landscape’ The industry is growing with stronger recognition of the advantages of Molecular Farming Moolec has a competitive edge in using both soybean and pea seeds Nobell Foods? Miruku? Mozza* Kyomei® mA > g > 6 A 2 6 ar Men) ar Mawes) Dairy Meat SCIENCE IN

  21. Slide 21: ~~ 2—

    ~~ 2—

  22. Slide 22: Moolec, a spin off from Bioceres Group

    Moolec, a spin off from Bioceres.Group) Science for a sustainable agriculture YS @ioceres S.A. - Private entity) Scientific team + Intelectual property, assets and approvals + Newly formed management and scientific leadership Science applied to alternative proteins SCIENCE IN

  23. Slide 23: Moolec's Pathway to Public Listing

    Moolec’s Pathway to Public.Listing, 10 years building our technology Technology scale-up Lab Pilot Patents Industrial scale Spin off From Safflower Company Expected plant Approvals Commercialization (UK Entity) to Soy Building Listing 4) yw Nasdaq @ © © © 2008 2014 Ri @ioceres S.A. - Private entity)

  24. Slide 24: World Class Team

    Gastén Paladini, MBA. ‘CEO & Co-Founder 10 years inthe traditional food industry as a Director of Paladin! (Group, one of the largest meat World.Class, Team Henk Hoogenkamp, PhD CPO & Co-Founder 10+ years in food and bio-materials ‘applications with special focus on ‘animal and plant-based proteins

  25. Slide 25: Board of Directors

    a & FedericoTrucco, Ph.D Bioceres' CEO since 201. Biochemist with a Ph.D degree in Crop Sciences from the University of Ilinois at Urbana-Champaign, In 2018 was recognized with the Konex, ‘Award, one of Argentina's most prestigious leadership awards, for business innovation. Since 2019 he is chairma

  26. Slide 26: Slide 26

  27. Slide 27: From farm to fork: Moolec's innovation and traceability

    From farm to fork: Moolec's innovation and traceability starts at the beginning of the food ingredients value chain Moolec D> . 5 Food cy Ke Unique - PI Ee Animal-free reducers ei, ontracter j i i 4 ili Croneres: ingredients Companies Retail / Food Consumers S Downstream Services Moolec’s IP Ingredi

  28. Slide 28: Product Portfolio

    _ a ‘Chymosin SPC Dairy Ingredients Plant-based chymosin, a key ingredient for cheese production compulsory for the clotting step = Bovine protein Enhanced plant-based ingredients with real animal proteins inside! : Safflower Product Portfolio. Shove GLA soNova* Nutritionals Oils Plant-based GLA oil

  29. Slide 29: Pipeline Status

    Pipeline Status, z =) Ae © R&D Prototype Scale-up Production Commercialization SAM 2025 eva, Dairy § }: Ingredients ¥ Be FF et tronte Nutritional Meat Replacement Lg emer Meat Replacement PR vescrrieie t Molec ] SeRnative

  30. Slide 30: Regulatory Pathway

    Regulatory Pathway, & & Cultivation Food 1. Cultivation approvals are not needed 1. Approvals: for food and feed (products world-wide and by-products) 2.Moolec cultivates inthe USA and 2.Codex Alimentarius Guidelines for Food Argentina Safety: * USA: Moolec's plants may not be subject — + USA: US-FD

  31. Slide 31: Patent Portfolio: IP Driven

    Patent Portfolio: JP.Driven, Moolec holds as owner and licensee an international patent portfolio for its Molecular Farming products andstands on a growing IP strategy with great understanding of the plant-biotech landscape offering a competitive advantage on its execution Current Potential 1P Oppor

  32. Slide 32: Today most consumers accept GMO food

    Today most consumers accept GMO.Food, 98% of all soybeans grown in the USA are GMO, and Impossible Burger's successful rollout confirmed that GMO is no longer a material issue in the US consumer's minds! Transparency and the cause's purpose are key tee ction idwide, suggests new sientifi Discussion

  33. Slide 33: Moolec addresses directly 10 of the 17 SDGs

    Moolec addresses directly 10.0f the 17, SDGs. We use SDGs and the 2030 Agenda as guidelines to strategically align our business in search of building a more equitable, resilent, and sustainable food system! | Moolec J ta; Pal as (@y SUSTAINABLE FF = ae CG Fi nding p rt rom el ing poverty, GOALS [4 :

  34. Slide 34: Go-To-Market

  35. Slide 35: Status and next steps

    2. GLA / Safflower FDA / Regulatory 4. Back Crossing Safflower Scaling up seed multiplication Chymosin Gi Chymosin x GLA Pre-submi BCI Stage1 Contracts, MOUs and MTAs 5. Partnership with grupoiNsup Global conglomerate with strong presence in the manufacture of biosimilars and other active ingredient

  36. Slide 36: Moolec's Future Plans

    | ws y Moolec's Future Fans Partnership with food Seed Product Pre-industrial producers and multiplication + age definition & scaling-up + New ingredients companies Field trials prototyping Regulatory approvals “Es3 acme

  37. Slide 37: Let's empower science in food

    Let’s empower science in food for the ( Moolec } [email protected] Cin} Follow us! ‘www.moolecscience.com

  38. Slide 38: Addendum

  39. Slide 39: Deal Team

    Deal Team Investment Team brings deep technology and deal experience Robert Bennett Chaiemen & CEO Will Bunker View Choirman & CFO Eric Ver Ploeg President Patrick Brandt \vP Corporate Dew LightJump + 25+ years equity sponsor in technology, advanced manufacturing. and dita mea + Co-Founder and CEO o

  40. Slide 40: LightJump

    LightJump. Digital Transformation Blockchain Mobility Category Cybersecurity Bank disintermediation Space Creators DTC Industrial { Mootec } STannarive

  41. Slide 41: Union Acquisition Group track record

    ion with an innovative, 1g growth company with in LATAM, on public k record of identifying, J, and promoting growing rial Sponsor with 2 of the essful De-SPAC transactions ‘of 329) and PROC (43rd of 329) in the top 13% as of June 7th 2022! + Union Acquistion + 1P0 oF Union pious + Closing of busines

  42. Slide 42: Bioceres Group

    Bioceres Group Vision Business Divisions Bioceres is Latin America’s Functional flagship group in the ag-biotech Foods WY BIOCERES space, advancing the life sciences ecosystem by investing in high impact technologies and science based companies Biomaterials Bioceres Bioceres Bioceres Tech Services C

Lightjump Acquisition — SPAC Merger (June 2022) on 6ix